L01FX03 • catumaxomab • Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Other monoclonal antibodies and antibody drug conjugates
Catumaxomab is a trifunctional monoclonal antibody used for the treatment of malignant ascites associated with epithelial cancers. It works by binding tumor cells, T cells, and accessory immune cells, thereby stimulating a strong immune response against cancer cells.
The medication is administered intraperitoneally, allowing localized action on tumor cells in the abdominal cavity. It is particularly indicated for patients who do not respond to standard therapies or are not eligible for other treatment options.
Patients should be closely monitored during treatment to detect potential adverse reactions, such as fever, abdominal pain, or hypersensitivity symptoms. It is important that the treatment is administered under strict medical supervision.
Common side effects include fever, nausea, vomiting, abdominal pain, and fatigue. In rare cases, severe allergic reactions may occur. Patients should inform their doctor of any unusual symptoms.
Substance: catumaxomab
Date of last drug list: 01-07-2015
Commercial code: W54344001
Concentration: 50mcg / 0.5ml
Pharmaceutical form: concentrate for solution for infusion
Quantity: 1
Product type: original
Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.